Multiple sclerosis (MS) research has increasingly focused on blood-based biomarkers to track disease activity, with recent clinical evaluations centering on neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP). While NfL levels reflect acute axonal damage and nerve fiber injury, investigators examine GFAP as an indicator of chronic neuroinflammation and glial scarring associated with the progressive, silent worsening of the condition over time.
Understanding the Role of Neurofilament Light Chain in MS Blood Tests
Blood tests designed to monitor multiple sclerosis progression rely heavily on the quantification of neurofilament light chain. NfL is a structural protein released into the extracellular fluid and bloodstream when neuronal axons are damaged. Elevated serum NfL concentrations typically correlate with acute inflammatory flare-ups, clinical relapses, and active focal lesions visible on magnetic resonance imaging (MRI) scans. Neurologists use these measurements to gauge the immediate impact of disease-modifying therapies on active neurodegeneration.
The Emergence of GFAP as a Marker for Gradual Disease Progression
Beyond acute relapses, researchers investigate the potential of the glial fibrillary acidic protein to track the insidious, progressive phase of multiple sclerosis that occurs independently of overt relapses. Unlike NfL, which highlights rapid axonal breakdown, GFAP is predominantly expressed by astrocytes—the star-shaped glial cells in the central nervous system. Elevated GFAP levels in blood plasma or cerebrospinal fluid reflect astrogliosis and chronic inflammation within the white and gray matter. This marker offers clinicians a window into the smoldering neurodegenerative processes that drive long-term disability accumulation even when standard clinical symptoms remain stable.
Clinical Implications for Long-Term Patient Management
The combination of NfL and GFAP measurements provides a dual-marker approach for comprehensive multiple sclerosis monitoring. Tracking both proteins allows medical teams to differentiate between acute inflammatory events and chronic, smoldering progression. As laboratories refine these blood assays, clinicians gain accessible tools to evaluate treatment efficacy earlier, adjust therapeutic strategies before irreversible disability occurs, and monitor disease trajectories with greater precision than traditional neuroimaging alone permits.
Next Steps in Biomarker Validation
Researchers continue to evaluate standardized reference ranges and longitudinal stability for GFAP and NfL assays across diverse patient cohorts. Ongoing clinical trials and observational studies aim to establish routine thresholds for these biomarkers in specialized neurology clinics, moving toward broader adoption in standard MS care protocols.
Related reading
